Search

Your search keyword '"Solomon, Scott"' showing total 6,859 results
Start Over Author "Solomon, Scott"
6,859 results on '"Solomon, Scott"'

101. Abstract 12936: Quality of Life Assessments as Inclusion Criteria in Heart Failure Clinical Trials

Author

Dimond, Matthew, Khan, Mohammad S, Fiuzat, Mona, Cleland, John G, Bhatt, Ankeet, Psotka, Mitchell, Anker, Stefan D, Butler, Javed, Felker, Michael, Mark, Daniel B, Carson, Peter E, Abraham, William T, Ahmad, Tariq, Lindenfeld, Joann, Vaduganathan, Muthiah, Whellan, David J, Vardeny, Orly, Solomon, Scott, Lewis, Eldrin F, Filippatos, Gerasimos, and OConnor, Christopher M

Published
2023
Full Text
View/download PDF

102. Abstract 12701: Safety and Tolerability of Angiotensin Receptor Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Drug Initiation Setting: A Subgroup Analysis of the PARADISE-MI Trial

Author

De Pasquale, Carmine, Claggett, Brian, Jering, Karola, McMurray, John J, Mann, Douglas L, Granger, Christopher, Kober, Lars, Lewis, Eldrin F, Maggioni, Aldo Pietro P, Rouleau, Jean L, Solomon, Scott, Steg, Philippe G, van der meer, peter, Braunwald, Eugene, and Pfeffer, Marc A

Published
2023
Full Text
View/download PDF

103. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m2: Insights From PARAGON-HF and PARADIGM-HF

Author

Chatur, Safia, Vaduganathan, Muthiah, Claggett, Brian L, McCausland, Finnian, Desai, Akshay S, Beldhuis, Iris, Rouleau, Jean L, Zile, Michael R, Packer, Milton, Pfeffer, Marc A, Lefkowitz, Martin P, McMurray, John J, and Solomon, Scott D

Published
2023
Full Text
View/download PDF

110. Foreword

Author

Braunwald, Eugene, primary, Libby, Peter, additional, Bonow, Robert O., additional, Mann, Douglas L., additional, Tomaselli, Gordon F, additional, Bhatt, Deepak L., additional, and Solomon, Scott D., additional

Published
2023
Full Text
View/download PDF

111. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Author

Vardeny, Orly, Fang, James C., Desai, Akshay S., Jhund, Pardeep S., Claggett, Brian, Vaduganathan, Muthiah, de Boer, Rudolf A., Hernandez, Adrian F., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., Kosiborod, Mikhail N., DeMets, David, O’Meara, Eileen, Zieroth, Shelley, Comin-Colet, Josep, Drozdz, Jaroslaw, Chiang, Chern-En, Kitakaze, Masafumi, Petersson, Magnus, Lindholm, Daniel, Langkilde, Anna Maria, McMurray, John J. V., and Solomon, Scott D.

Published
2023
Full Text
View/download PDF

112. Cardiovascular implications of COVID-19 versus influenza infection: a review.

Author

Khan, Muhammad Shahzeb, Shahid, Izza, Anker, Stefan D, Solomon, Scott D, Vardeny, Orly, Michos, Erin D, Fonarow, Gregg C, and Butler, Javed

Subjects
Humans, Cardiovascular Diseases, Adult, Middle Aged, Female, Male, Influenza, Human, Coinfection, COVID-19, SARS-CoV-2, Influenza, Human, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundDue to the overlapping clinical features of coronavirus disease 2019 (COVID-19) and influenza, parallels are often drawn between the two diseases. Patients with pre-existing cardiovascular diseases (CVD) are at a higher risk for severe manifestations of both illnesses. Considering the high transmission rate of COVID-19 and with the seasonal influenza approaching in late 2020, the dual epidemics of COVID-19 and influenza pose serious cardiovascular implications. This review highlights the similarities and differences between influenza and COVID-19 and the potential risks associated with coincident pandemics.Main bodyCOVID-19 has a higher mortality compared to influenza with case fatality rate almost 15 times more than that of influenza. Additionally, a significantly increased risk of adverse outcomes has been noted in patients with CVD, with ~ 15 to 70% of COVID-19 related deaths having an underlying CVD. The critical care need have ranged from 5 to 79% of patients hospitalized due to COVID-19, a proportion substantially higher than with influenza. Similarly, the frequency of vascular thrombosis including deep venous thrombosis and pulmonary embolism is markedly higher in COVID-19 patients compared with influenza in which vascular complications are rarely seen. Unexpectedly, while peak influenza season is associated with increased cardiovascular hospitalizations, a decrease of ~ 50% in cardiovascular hospitalizations has been observed since the first diagnosed case of COVID-19, owing in part to deferred care.ConclusionIn the coming months, increasing efforts towards evaluating new interventions will be vital to curb COVID-19, especially as peak influenza season approaches. Currently, not enough data exist regarding co-infection of COVID-19 with influenza or how it would progress clinically, though it may cause a significant burden on an already struggling health care system. Until an effective COVID-19 vaccination is available, high coverage of influenza vaccination should be of utmost priority.

Published
2020

113. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant

Author

Solomon, Scott R, Martin, Andrew St, Zhang, Mei-Jie, Ballen, Karen, Bashey, Asad, Battiwalla, Minoo, Baxter-Lowe, Lee Ann, Brunstein, Claudio, Chhabra, Saurabh, Perez, Miguel Angel Diaz, Fuchs, Ephraim J, Ganguly, Siddhartha, Hardy, Nancy, Hematti, Peiman, McGuirk, Joseph, Peres, Edward, Ringden, Olle, Rizzieri, David, Romee, Rizwan, Solh, Melhem, Szwajcer, David, van der Poel, Marjolein, Waller, Edmund, William, Basem M, and Eapen, Mary

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Stem Cell Research, Stem Cell Research - Nonembryonic - Human, Clinical Research, Transplantation, Hematology, Stem Cell Research - Umbilical Cord Blood/ Placenta - Human, Rare Diseases, Cancer, Regenerative Medicine, Stem Cell Research - Umbilical Cord Blood/ Placenta, Good Health and Well Being, Black or African American, Cord Blood Stem Cell Transplantation, Fetal Blood, Graft vs Host Disease, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Alternative donor, African American, Caucasian, race, leukemia, transplant-related mortality, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

Although hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P < .0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P = .008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P = .51), overall survival (54% versus 57%; P = .66), or disease-free survival (43% versus 47%; P = .46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies.

Published
2020

114. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Author

Vardeny, Orly, Fang, James C., Desai, Akshay S., Jhund, Pardeep S., Claggett, Brian, Vaduganathan, Muthiah, de Boer, Rudolf A., Hernandez, Adrian F., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., Kosiborod, Mikhail N., DeMets, David, O’Meara, Eileen, Zieroth, Shelley, Comin-Colet, Josep, Drozdz, Jaroslaw, Chiang, Chern-En, Kitakaze, Masafumi, Petersson, Magnus, Lindholm, Daniel, Langkilde, Anna Maria, McMurray, John J. V., and Solomon, Scott D.

Published
2022
Full Text
View/download PDF

116. Nationwide Utilization of Danish Government Electronic letter system for increasing inFLUenza vaccine uptake (NUDGE-FLU): Study protocol for a nationwide randomized implementation trial

Author

Johansen, Niklas Dyrby, Vaduganathan, Muthiah, Bhatt, Ankeet S., Lee, Simin Gharib, Modin, Daniel, Claggett, Brian L., Dueger, Erica L., Samson, Sandrine, Loiacono, Matthew M., Køber, Lars, Solomon, Scott D., Sivapalan, Pradeesh, Jensen, Jens Ulrik Stæhr, Valentiner-Branth, Palle, Krause, Tyra Grove, and Biering-Sørensen, Tor

Published
2023
Full Text
View/download PDF

117. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

Author

Lanfear, David E., Njoroge, Joyce N., Adams, Kirkwood F., Anand, Inder, Fang, James C., Ramires, Felix, Sliwa-Hahnle, Karen, Badat, Aysha, Burgess, Lesley, Gorodeski, Eiran Z., Williams, Celeste, Diaz, Rafael, Felker, Gary M., McMurray, John J.V., Metra, Marco, Solomon, Scott, Miao, Zi Michael, Claggett, Brian L., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., and Teerlink, John R.

Published
2023
Full Text
View/download PDF

118. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Author

Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, and Kamdar, Manali

Published
2023
Full Text
View/download PDF

120. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum

Author

Butt, Jawad H., Docherty, Kieran F., Claggett, Brian L., Desai, Akshay S., Fang, James C., Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., Cabrera Honorio, Jose Walter, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Køber, Lars, Lam, Carolyn S.P., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Vardeny, Orly, O'Meara, Eileen, Saraiva, Jose F.K., Shah, Sanjiv J., Vaduganathan, Muthiah, Jhund, Pardeep S., Solomon, Scott D., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

121. Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial

Author

Johansen, Niklas Dyrby, Vaduganathan, Muthiah, Bhatt, Ankeet S, Lee, Simin Gharib, Modin, Daniel, Claggett, Brian L, Dueger, Erica L, Samson, Sandrine I, Loiacono, Matthew M, Køber, Lars, Solomon, Scott D, Sivapalan, Pradeesh, Jensen, Jens Ulrik Stæhr, Martel, Cyril Jean-Marie, Valentiner-Branth, Palle, Krause, Tyra Grove, and Biering-Sørensen, Tor

Published
2023
Full Text
View/download PDF

122. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

Author

Dholaria, Bhagirathbhai, Savani, Bipin N, Labopin, Myriam, Luznik, Leo, Ruggeri, Annalisa, Mielke, Stephan, Malki, Monzr M Al, Kongtim, Piyanuch, Fuchs, Ephraim, Huang, Xiao-Jun, Locatelli, Franco, Aversa, Franco, Castagna, Luca, Bacigalupo, Andrea, Martelli, Massimo, Blaise, Didier, Soussan, Patrick Ben, Arnault, Yolande, Handgretinger, Rupert, Roy, Denis-Claude, O’Donnell, Paul, Bashey, Asad, Solomon, Scott, Romee, Rizwan, Lewalle, Philippe, Gayoso, Jorge, Maschan, Michael, Lazarus, Hillard M, Ballen, Karen, Giebel, Sebastian, Baron, Frederic, Ciceri, Fabio, Esteve, Jordi, Gorin, Norbert-Claude, Spyridonidis, Alexandros, Schmid, Christoph, Ciurea, Stefan O, Nagler, Arnon, and Mohty, Mohamad

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Transplantation, Cancer, Regenerative Medicine, Rare Diseases, Prevention, Hematology, Stem Cell Research, Inflammatory and immune system, Consensus, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Lymphocytes, Prospective Studies, Retrospective Studies, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

Published
2020

123. Pre-existing traits associated with Covid-19 illness severity

Author

Ebinger, Joseph E, Achamallah, Natalie, Ji, Hongwei, Claggett, Brian L, Sun, Nancy, Botting, Patrick, Nguyen, Trevor-Trung, Luong, Eric, Kim, Elizabeth H, Park, Eunice, Liu, Yunxian, Rosenberry, Ryan, Matusov, Yuri, Zhao, Steven, Pedraza, Isabel, Zaman, Tanzira, Thompson, Michael, Raedschelders, Koen, Berg, Anders H, Grein, Jonathan D, Noble, Paul W, Chugh, Sumeet S, Merz, C Noel Bairey, Marbán, Eduardo, Van Eyk, Jennifer E, Solomon, Scott D, Albert, Christine M, Chen, Peter, and Cheng, Susan

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Clinical Sciences, Health Sciences, Aging, Clinical Research, Infectious Diseases, Management of diseases and conditions, 7.1 Individual care needs, Metabolic and endocrine, Good Health and Well Being, Adolescent, Adult, Black or African American, Age Factors, Aged, Aged, 80 and over, Betacoronavirus, COVID-19, Child, Comorbidity, Coronavirus Infections, Critical Care, Diabetes Mellitus, Female, Hospitalization, Humans, Los Angeles, Male, Middle Aged, Obesity, Pandemics, Pneumonia, Viral, Retrospective Studies, Risk Factors, SARS-CoV-2, Young Adult, General Science & Technology
Abstract

ImportanceCertain individuals, when infected by SARS-CoV-2, tend to develop the more severe forms of Covid-19 illness for reasons that remain unclear.ObjectiveTo determine the demographic and clinical characteristics associated with increased severity of Covid-19 infection.DesignRetrospective observational study. We curated data from the electronic health record, and used multivariable logistic regression to examine the association of pre-existing traits with a Covid-19 illness severity defined by level of required care: need for hospital admission, need for intensive care, and need for intubation.SettingA large, multihospital healthcare system in Southern California.ParticipantsAll patients with confirmed Covid-19 infection (N = 442).ResultsOf all patients studied, 48% required hospitalization, 17% required intensive care, and 12% required intubation. In multivariable-adjusted analyses, patients requiring a higher levels of care were more likely to be older (OR 1.5 per 10 years, P

Published
2020

124. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Author

Butler, Javed, Packer, Milton, Greene, Stephen J, Fiuzat, Mona, Anker, Stefan D, Anstrom, Kevin J, Carson, Peter E, Cooper, Lauren B, Fonarow, Gregg C, Hernandez, Adrian F, Januzzi, James L, Jessup, Mariell, Kalyani, Rita R, Kaul, Sanjay, Kosiborod, Mikhail, Lindenfeld, JoAnn, McGuire, Darren K, Sabatine, Marc S, Solomon, Scott D, Teerlink, John R, Vaduganathan, Muthiah, Yancy, Clyde W, Stockbridge, Norman, and O'Connor, Christopher M

Subjects
Cardiovascular, Clinical Trials and Supportive Activities, Clinical Research, Heart Disease, Heart Disease - Coronary Heart Disease, Diabetes, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Endpoint Determination, Heart Failure, Humans, Research Report, Sodium-Glucose Transporter 2, Sodium-Glucose Transporter 2 Inhibitors, Treatment Outcome, biomarkers, clinical trial, diabetes mellitus, type 2, heart failure, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Public Health and Health Services, Cardiovascular System & Hematology
Abstract

Following regulatory guidance set forth in 2008 by the US Food and Drug Administration for new drugs for type 2 diabetes mellitus, many large randomized, controlled trials have been conducted with the primary goal of assessing the safety of antihyperglycemic medications on the primary end point of major adverse cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Heart failure (HF) was not specifically mentioned in the US Food and Drug Administration guidance and therefore it was not a focus of these studies when planned. Several trials subsequently showed the impact of antihyperglycemic drugs on HF outcomes, which were not originally specified as the primary end point of the trials. The most impressive finding has been the substantial and consistent risk reduction in HF hospitalization seen across 4 trials of sodium glucose cotransporter 2 inhibitors. However, to date, these results have not led to regulatory approval of any of these drugs for a HF indication or a recommendation for use by US HF guidelines. It is therefore important to explore to what extent persuasive treatment effects on nonprimary end points can be used to support regulatory claims and guideline recommendations. This topic was discussed by researchers, clinicians, industry sponsors, regulators, and representatives from professional societies, who convened on the US Food and Drug Administration campus on March 6, 2019. This report summarizes these discussions and the key takeaway messages from this meeting.

Published
2019

125. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

Author

Solomon, Scott, St Martin, Andrew, Shah, Nirav, Fatobene, Giancarlo, Al Malki, Monzr, Ballen, Karen, Bashey, Asad, Bejanyan, Nelli, Bolaños Meade, Javier, Brunstein, Claudio, DeFilipp, Zachariah, Champlin, Richard, Fuchs, Ephraim, Hamadani, Mehdi, Hematti, Peiman, Kanakry, Christopher, McGuirk, Joseph, McNiece, Ian, Ciurea, Stefan, Pasquini, Marcelo, Rocha, Vanderson, Romee, Rizwan, Patel, Sagar, Vasu, Sumithira, Waller, Edmund, Wingard, John, Zhang, Mei-Jie, and Eapen, Mary

Subjects
Adolescent, Adult, Disease-Free Survival, Female, Hematologic Neoplasms, Humans, Middle Aged, Myeloablative Agonists, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract

In the absence of prospective studies that examine the effect of conditioning regimen intensity after T-cell-replete haploidentical transplant for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS), a retrospective cohort analysis was performed. Of the 1325 eligible patients (AML, n = 818; ALL, n = 286; and MDS, n = 221), 526 patients received a myeloablative regimen and 799 received a reduced-intensity regimen. Graft-versus-host disease prophylaxis was uniform with posttransplant cyclophosphamide, a calcineurin inhibitor, and mycophenolate mofetil. The primary end point was disease-free survival. Cox regression models were built to study the effect of conditioning regimen intensity on transplant outcomes. For patients aged 18 to 54 years, disease-free survival was lower (hazard ratio [HR], 1.34; 42% vs 51%; P = .007) and relapse was higher (HR, 1.51; 44% vs 33%; P = .001) with a reduced-intensity regimen compared with a myeloablative regimen. Nonrelapse mortality did not differ according to regimen intensity. For patients aged 55 to 70 years, disease-free survival (HR, 0.97; 37% vs 43%; P = .83) and relapse (HR, 1.32; 42% vs 31%; P = .11) did not differ according to regimen intensity. Nonrelapse mortality was lower with reduced-intensity regimens (HR, 0.64; 20% vs 31%; P = .02). Myeloablative regimens are preferred for AML, ALL, and MDS; reduced-intensity regimens should be reserved for those unable to tolerate myeloablation.

Published
2019

126. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF

Author

Adamson, Carly, Welsh, Paul, Docherty, Kieran F., de Boer, Rudolf A., Diez, Mirta, Drożdż, Jarosław, Dukát, Andre, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Ljungman, Charlotta E.A., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Morrow, David A., Lindholm, Daniel, Hammarstedt, Ann, Boulton, David W., Greasley, Peter J., Langkilde, Anna Maria, Solomon, Scott D., Sattar, Naveed, McMurray, John J.V., and Jhund, Pardeep S.

Published
2023
Full Text
View/download PDF

128. Coronary Flow Reserve, Inflammation, and Myocardial Strain: The CIRT-CFR Trial

Author

Taqueti, Viviany R., Shah, Amil M., Everett, Brendan M., Pradhan, Aruna D., Piazza, Gregory, Bibbo, Courtney, Hainer, Jon, Morgan, Victoria, Carolina do A. H. de Souza, Ana, Skali, Hicham, Blankstein, Ron, Dorbala, Sharmila, Goldhaber, Samuel Z., Le May, Michel R., Chow, Benjamin J.W., deKemp, Robert A., Hage, Fadi G., Beanlands, Rob S., Libby, Peter, Glynn, Robert J., Solomon, Scott D., Ridker, Paul M., and Di Carli, Marcelo F.

Published
2023
Full Text
View/download PDF

131. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

Author

Jhund, Pardeep S., Kondo, Toru, Butt, Jawad H., Docherty, Kieran F., Claggett, Brian L., Desai, Akshay S., Vaduganathan, Muthiah, Gasparyan, Samvel B., Bengtsson, Olof, Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Køber, Lars, Lam, Carolyn S. P., Martinez, Felipe A., Sabatine, Marc S., Shah, Sanjiv J., Solomon, Scott D., and McMurray, John J. V.

Published
2022
Full Text
View/download PDF

135. Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial

Author

De Pasquale, Carmine G., primary, Claggett, Brian, additional, Jering, Karola, additional, McMurray, John J.V., additional, Mann, Douglas, additional, Miao, Zi Michael, additional, Granger, Christopher B., additional, Køber, Lars, additional, Maggioni, Aldo P., additional, Rouleau, Jean-Lucien, additional, Solomon, Scott D., additional, Steg, Philippe Gabriel, additional, van der Meer, Peter, additional, Braunwald, Eugene, additional, and Pfeffer, Marc A., additional

Published
2024
Full Text
View/download PDF

137. Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2

Author

Chatur, Safia, primary, Beldhuis, Iris E., additional, Claggett, Brian L., additional, McCausland, Finnian R., additional, Neuen, Brendon L., additional, Desai, Akshay S., additional, Rouleau, Jean L., additional, Zile, Michael R., additional, Packer, Milton, additional, Pfeffer, Marc A., additional, Lefkowitz, Martin P., additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Vaduganathan, Muthiah, additional

Published
2024
Full Text
View/download PDF

138. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial

Author

Lassen, Mats Christian Højbjerg, primary, Ostrominski, John W., additional, Inzucchi, Silvio E., additional, Claggett, Brian L., additional, Kulac, Ian, additional, Jhund, Pardeep, additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S.P., additional, Martinez, Felipe A., additional, Shah, Sanjiv J., additional, Desai, Akshay S., additional, Petersson, Magnus, additional, Langkilde, Anna Maria, additional, Docherty, Kieran F., additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Vaduganathan, Muthiah, additional

Published
2024
Full Text
View/download PDF

139. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial

Author

Vaduganathan, Muthiah, primary, Claggett, Brian L., additional, Lam, Carolyn S.P., additional, Pitt, Bertram, additional, Senni, Michele, additional, Shah, Sanjiv J., additional, Voors, Adriaan A., additional, Zannad, Faiez, additional, Desai, Akshay S., additional, Jhund, Pardeep S., additional, Viswanathan, Prabhakar, additional, Bomfim Wirtz, Antonieta, additional, Schloemer, Patrick, additional, Lay‐Flurrie, James, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2024
Full Text
View/download PDF

140. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Author

Maron, Martin S., primary, Masri, Ahmad, additional, Nassif, Michael E., additional, Barriales-Villa, Roberto, additional, Arad, Michael, additional, Cardim, Nuno, additional, Choudhury, Lubna, additional, Claggett, Brian, additional, Coats, Caroline J., additional, Düngen, Hans-Dirk, additional, Garcia-Pavia, Pablo, additional, Hagège, Albert A., additional, Januzzi, James L., additional, Lee, Matthew M.Y., additional, Lewis, Gregory D., additional, Ma, Chang-Sheng, additional, Michels, Michelle, additional, Olivotto, Iacopo, additional, Oreziak, Artur, additional, Owens, Anjali T., additional, Spertus, John A., additional, Solomon, Scott D., additional, Tfelt-Hansen, Jacob, additional, van Sinttruije, Marion, additional, Veselka, Josef, additional, Watkins, Hugh, additional, Jacoby, Daniel L., additional, Heitner, Stephen B., additional, Kupfer, Stuart, additional, Malik, Fady I., additional, Meng, Lisa, additional, Wohltman, Amy, additional, and Abraham, Theodore P., additional

Published
2024
Full Text
View/download PDF

141. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

Author

Solomon, Scott D., primary, Ostrominski, John W., additional, Vaduganathan, Muthiah, additional, Claggett, Brian, additional, Jhund, Pardeep S., additional, Desai, Akshay S., additional, Lam, Carolyn S.P., additional, Pitt, Bertram, additional, Senni, Michele, additional, Shah, Sanjiv J., additional, Voors, Adriaan A., additional, Zannad, Faiez, additional, Abidin, Imran Zainal, additional, Alcocer‐Gamba, Marco Antonio, additional, Atherton, John J., additional, Bauersachs, Johann, additional, Ma, Chang‐Sheng, additional, Chiang, Chern‐En, additional, Chioncel, Ovidiu, additional, Chopra, Vijay, additional, Comin‐Colet, Josep, additional, Filippatos, Gerasimos, additional, Fonseca, Cândida, additional, Gajos, Grzegorz, additional, Goland, Sorel, additional, Goncalvesová, Eva, additional, Kang, Seok‐Min, additional, Katova, Tzvetana, additional, Kosiborod, Mikhail N., additional, Latkovskis, Gustavs, additional, Lee, Alex Pui‐Wai, additional, Linssen, Gerard C.M., additional, Llamas‐Esperón, Guillermo, additional, Mareev, Vyacheslav, additional, Martinez, Felipe A., additional, Melenovský, Vojtěch, additional, Merkely, Béla, additional, Nodari, Savina, additional, Petrie, Mark C., additional, Saldarriaga, Clara Inés, additional, Saraiva, Jose Francisco Kerr, additional, Sato, Naoki, additional, Schou, Morten, additional, Sharma, Kavita, additional, Troughton, Richard, additional, Udell, Jacob A., additional, Ukkonen, Heikki, additional, Vardeny, Orly, additional, Verma, Subodh, additional, von Lewinski, Dirk, additional, Voronkov, Leonid G., additional, Yilmaz, Mehmet Birhan, additional, Zieroth, Shelley, additional, Lay‐Flurrie, James, additional, van Gameren, Ilse, additional, Amarante, Flaviana, additional, Viswanathan, Prabhakar, additional, and McMurray, John J.V., additional

Published
2024
Full Text
View/download PDF

143. Design and rationale for MAGNITUDE, a phase 3, randomized, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)

Author

S., Mathew, primary, Fontana, Marianna, primary, Claggett, Brian, primary, Hernandez, Adrian, primary, L., James, primary, Lam, Carolyn, primary, Lewis, Eldrin, primary, García-Pavía, Pablo, primary, J., Sanjiv, primary, Solomon, Scott, primary, Gutstein, David, primary, D., Michael, primary, Anderson, Lisa, primary, and Olbertz, Joy, primary

Published
2024
Full Text
View/download PDF

144. Association of Cumulative Systolic Blood Pressure with Left Atrial Function in the Setting of Normal Left Atrial Size: the Atherosclerosis Risk in Communities (ARIC) Study

Author

Van’t Hof, Jeremy R., primary, Parikh, Romil, additional, Moser, Ethan D., additional, Inciardi, Riccardo M., additional, Matsushita, Kunihiro, additional, Soliman, Elsayed Z., additional, Alonso, Alvaro, additional, Shah, Amil M., additional, Solomon, Scott D., additional, Lutsey, Pamela L., additional, and Chen, Lin Yee, additional

Published
2024
Full Text
View/download PDF

145. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis

Author

Ostrominski, John W., primary, Claggett, Brian L., additional, Miao, Zi Michael, additional, Mc Causland, Finnian R., additional, Anand, Inder S., additional, Desai, Akshay S., additional, Jhund, Pardeep S., additional, Lam, Carolyn S.P., additional, Pfeffer, Marc A., additional, Pitt, Bertram, additional, Zannad, Faiez, additional, Zile, Michael R., additional, Bomfim Wirtz, Antonieta, additional, Lay-Flurrie, James, additional, Viswanathan, Prabhakar, additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Vaduganathan, Muthiah, additional

Published
2024
Full Text
View/download PDF

146. Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

Author

Rodriguez-Otero, Paula, primary, Ailawadhi, Sikander, additional, Arnulf, Bertrand, additional, Patel, Krina, additional, Cavo, Michele, additional, Nooka, Ajay K, additional, Manier, Salomon, additional, Callander, Natalie, additional, Costa, Luciano J, additional, Vij, Ravi, additional, Bahlis, Nizar J, additional, Moreau, Philippe, additional, Solomon, Scott R, additional, Delforge, Michel, additional, Berdeja, Jesus, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Favre-Kontula, Linda, additional, Wu, Fan, additional, Piasecki, Julia, additional, Cook, Mark, additional, and Giralt, Sergio, additional

Published
2024
Full Text
View/download PDF

147. Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction

Author

Patel, Ravi B., primary, Silvestry, Frank E., additional, Komtebedde, Jan, additional, Solomon, Scott D., additional, Hasenfuß, Gerd, additional, Litwin, Sheldon E., additional, Borlaug, Barry A., additional, Price, Matthew J., additional, Kawash, Rami, additional, Hummel, Scott L., additional, Cutlip, Donald E., additional, Leon, Martin B., additional, van Veldhuisen, Dirk J., additional, Rieth, Andreas J., additional, McKenzie, Scott, additional, Bugger, Heiko, additional, Mazurek, Jeremy A., additional, Kapadia, Samir R., additional, Vanderheyden, Marc, additional, Ky, Bonnie, additional, and Shah, Sanjiv J., additional

Published
2024
Full Text
View/download PDF

148. Electronic nudges increase influenza vaccination utilization after myocardial infarction: the nationwide NUDGE-FLU implementation trial

Author

Bhatt, Ankeet S, primary, Johansen, Niklas Dyrby, additional, Modin, Daniel, additional, Claggett, Brian L, additional, Dueger, Erica L, additional, Samson, Sandrine I, additional, Loiacono, Matthew M, additional, Køber, Lars, additional, Solomon, Scott D, additional, Sivapalan, Pradeesh, additional, Jensen, Jens Ulrik Stæhr, additional, Martel, Cyril Jean-Marie, additional, Vaduganathan, Muthiah, additional, and Biering-Sørensen, Tor, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results